364
Participants
Start Date
October 31, 2012
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
Placebo MDPI
Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
Albuterol MDPI
Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
Teva Investigational Site 10169, Huntington Beach
Teva Investigational Site 10157, San Diego
Teva Investigational Site 10148, Denver
Teva Investigational Site 10159, Denver
Teva Investigational Site 10158, Miami
Teva Investigational Site 10168, Miami
Teva Investigational Site 10154, Gainesville
Teva Investigational Site 10161, Louisville
Teva Investigational Site 10162, Bethesda
Teva Investigational Site 10166, Wheaton
Teva Investigational Site 10151, Minneapolis
Teva Investigational Site 10142, Plymouth
Teva Investigational Site 10152, St Louis
Teva Investigational Site 10146, Bellevue
Teva Investigational Site 10160, Skillman
Teva Investigational Site 10144, Rochester
Teva Investigational Site 10141, High Point
Teva Investigational Site 10153, Raleigh
Teva Investigational Site 10147, Canton
Teva Investigational Site 10143, Cincinnati
Teva Investigational Site 10167, Sylvania
Teva Investigational Site 10150, Eugene
Teva Investigational Site 10156, Portland
Teva Investigational Site 10155, El Paso
Teva Investigational Site 10149, New Braunfels
Teva Investigational Site 10145, San Antonio
Teva Investigational Site 10170, San Antonio
Teva Investigational Site 10163, Burke
Teva Investigational Site 10165, Seattle
Teva Investigational Site 10164, Greenfield
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY